GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » Float Percentage Of Total Shares Outstanding

enGene Holdings (enGene Holdings) Float Percentage Of Total Shares Outstanding : 71.48% (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, enGene Holdings's float shares is 31.52 Mil. enGene Holdings's total shares outstanding is 44.10 Mil. enGene Holdings's float percentage of total shares outstanding is 71.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, enGene Holdings's Insider Ownership is 7.17%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, enGene Holdings's Institutional Ownership is 1.85%.

enGene Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

enGene Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=31.52/44.10
=71.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Holdings (enGene Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
Traded in Other Exchanges
N/A
Address
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
Website
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Executives
Richard M Glickman director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson director, officer: Chief Executive Officer 8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Fonds De Solidarite Des Travailleurs Du Quebec 10 percent owner 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Gerald A Brunk director C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos director BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan officer: Int. Chief Financial Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung officer: Chief Technology Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols officer: Pres. & Chief Operating Ofc. 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan officer: Chief Scientific Officer 7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v. 10 percent owner GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Opportunities Fund I Cooperatief U.a. 10 percent owner GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Forbion Growth Management B.v. 10 percent owner C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807

enGene Holdings (enGene Holdings) Headlines

From GuruFocus

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

By PRNewswire • 12-22-2023

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

By PRNewswire • 12-19-2023

enGene Appoints Ryan Daws as Chief Financial Officer

By PRNewswire • 11-29-2023